Liraglutide in Children Under 12: What Families Need to Know About Transitioning to Adult Care

What Liraglutide Is, and Where the Age Line Actually Falls

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist given by daily subcutaneous injection. Two branded formulations exist in the United States: Victoza (1.2 mg or 1.8 mg), approved for type 2 diabetes, and Saxenda (titrated up to 3.0 mg), approved for chronic weight management. They are the same molecule at different doses for different indications, not interchangeable products.

Saxenda's obesity approval is limited to patients aged 12 and older. Victoza's diabetes approval extends down to age 10. Neither approval was extended to younger children, because the pivotal trials did not enroll them.

No randomized trial has tested liraglutide in children younger than these thresholds, so any use in a younger child is off-label and extrapolated, not directly supported by controlled pediatric evidence. That distinction, extrapolated versus directly studied, is the single most important thing a family or referring clinician needs to hold onto before making decisions about a child under 10 or 12.

Why the Age Floor Exists

Victoza's pediatric approval for type 2 diabetes came from the ELLIPSE trial, which enrolled 134 patients aged 10 to 17 [1]. Saxenda's pediatric obesity approval came from SCALE Kids (NCT02741674), which enrolled patients aged 12 to 17 [2]. Children younger than these bands were not studied in either program, and the approvals were not extrapolated downward.

The FDA label for Saxenda states: "The safety and effectiveness of Saxenda in pediatric patients below the age of 12 years have not been established." [3] That is a statement that no controlled data exist for that age group, not a minor caveat. Off-label prescribing below age 10 or 12 happens on a case-by-case basis, generally at academic pediatric obesity or endocrinology centers, without trial-level evidence to guide dosing or safety monitoring in that specific subgroup.

What the Trials That Support Current Approvals Actually Showed

ELLIPSE: Liraglutide for Pediatric Type 2 Diabetes (Ages 10 to 17)

ELLIPSE randomized 134 participants aged 10 to 17 to liraglutide 1.8 mg/day or placebo, added to metformin with or without basal insulin [1]. At 26 weeks, HbA1c fell by 0.64 percentage points with liraglutide and rose by 0.42 percentage points with placebo, a between-group difference of 1.06 percentage points (P<0.001). The trial, published in the New England Journal of Medicine in 2019, reported nausea in 64% of liraglutide-treated participants versus 36% of placebo participants, and no cases of pancreatitis or thyroid malignancy during the study period. Readers who need exact adverse-event tables should confirm against the published trial report rather than relying on a secondary summary.

SCALE Kids: Liraglutide for Adolescent Obesity (Ages 12 to 17)

SCALE Kids enrolled 251 adolescents aged 12 to 17 with obesity, randomized 2:1 to liraglutide 3.0 mg/day or placebo for 56 weeks [2]. BMI standard deviation score fell by roughly 0.22 units with liraglutide compared with essentially no change on placebo, and body weight decreased by about 4.5 kg with liraglutide versus an increase of roughly 1.6 kg on placebo. These are the numbers most often quoted to families deciding whether to start therapy in an adolescent, and they apply to the 12-to-17 population studied, not to younger children.

Why These Numbers Cannot Simply Be Moved Down in Age

Neither trial enrolled children under 10 (diabetes) or under 12 (obesity). Prepubertal children differ from adolescents in body composition and in the hormonal signals that regulate appetite and energy balance, which is one reason pediatric specialists are cautious about assuming adolescent trial results apply unchanged to a 7- or 9-year-old. This is a plausible mechanistic concern drawn from general pediatric endocrine physiology, not a finding from a liraglutide-specific study in that age group, and it should be read as background reasoning rather than direct evidence.

Use in children under 10 or 12 should occur only within a specialized academic center with ethics oversight, or as part of a registered clinical trial, given the absence of controlled safety and dosing data.

What Is Established, What Is Extrapolated, and What Is Not Known

Established: Liraglutide has FDA-approved, trial-supported indications in adolescents aged 12 to 17 (obesity, via SCALE Kids) and children aged 10 to 17 (type 2 diabetes, via ELLIPSE) [1][2][3][9].

Plausible but unproven: That the adolescent dose-response and safety profile translate reasonably well to children just below the approved age floor (for example, ages 9 to 11) is a clinical assumption some academic centers act on off-label, but it has not been tested in a controlled trial.

Not established: Efficacy, safe dosing, and long-term safety (including thyroid and pancreatic risk) in children under 10. Cardiovascular outcome data such as the LEADER trial come from adults with elevated cardiovascular risk and cannot be assumed to apply to pediatric or young-adult patients [11].

Evidence and Transferability Map for This Population

The table below separates what liraglutide trials directly demonstrated from what a clinician would be extrapolating, and identifies where specialist input is required and what to monitor at each stage. It is intended as a planning aid for clinicians and families, not a substitute for individualized medical judgment.

Moving From Pediatric to Adult Care: What a Real Transition Looks Like

Health care transition is usually described in pediatric literature as a planned, purposeful process of moving an adolescent from child-centered to adult-oriented care, rather than a single handoff appointment; this framing is echoed in pediatric clinical guidance on supporting health care transitions. For a patient who has been on liraglutide since age 12 or 13, the transition window typically opens around age 16 to 17 and should be complete well before the patient's care lapses entirely.

Readiness Assessment

The Got Transition program, a federally supported national resource, outlines a six-core-element framework covering transition policy, tracking, readiness assessment, planning, transfer, and integration into adult care. Applied to a liraglutide patient specifically, a readiness conversation should confirm that the patient:

• Can self-administer injections without prompting
• Understands the titration schedule and what to do if a dose is missed
• Recognizes signs of hypoglycemia, particularly if also on metformin or insulin
• Can state their own treatment goals (HbA1c target, weight or BMI trajectory, or both)
• Knows the pen's storage requirements (refrigerated until first use, then room temperature per the label's stated window)

Choosing the Adult Provider

Not every adult primary care physician is comfortable managing liraglutide at the 3.0 mg obesity dose. Adult endocrinologists and obesity medicine physicians are generally the most appropriate receiving providers. The Obesity Medicine Association maintains a public member finder that can help locate a qualified physician [8]. Families should start this search well before the anticipated transfer date rather than waiting until the last pediatric visit.

The Records Handoff

A useful handoff package for the adult provider includes:

• Liraglutide dose history: starting dose, titration dates, current dose, and any reductions due to side effects
• Growth and BMI trajectory from the pediatric record
• HbA1c trend data, for diabetes patients
• Documentation of adverse events (nausea requiring dose reduction, injection site reactions, elevated lipase)
• Any prior thyroid ultrasound or calcitonin result, if one was obtained
• Current comorbidity list and medication reconciliation

Dosing Across the Transition: What Should and Should Not Change

A common failure point at transition is an adult provider unnecessarily restarting titration, or skipping a monitoring step the pediatric team had already established. A brief written summary at the point of transfer prevents both problems.

Saxenda (Obesity) Titration

The FDA-approved schedule starts at 0.6 mg/day and increases roughly weekly to 3.0 mg/day by around week 5 [3]. A patient already stable at 3.0 mg generally should not be retitrated. If a patient has stopped liraglutide for an extended gap, commonly because insurance authorization lapsed during the transition, restarting at the full 3.0 mg dose meaningfully increases nausea and vomiting risk; retitrating from 0.6 mg is the safer approach in that situation, and the exact restart threshold should be confirmed with the prescribing clinician rather than assumed.

Victoza (Type 2 Diabetes) Titration

Victoza is typically started at 0.6 mg/day for at least a week, then increased to 1.2 mg/day, with a further increase to 1.8 mg/day if glycemic control remains inadequate [9]. The 0.6 mg dose provides minimal glycemic effect and exists mainly to reduce GI side effects during initiation. A patient arriving from pediatric care already stable on 1.8 mg generally should continue that dose, with HbA1c reassessed around 12 weeks post-transfer.

Insurance and Coverage During the Age Transition

Coverage for Saxenda in obesity commonly requires prior authorization, and it is common for plans to require renewed documentation when a patient moves off a parent's policy or between pediatric and adult coverage programs. Exact requirements vary by plan and by state, so families should confirm directly with the new insurer rather than assume continuity, and should start that conversation as early as practical once a transfer date is anticipated. The documentation an adult prescriber typically needs mirrors the adult label's criteria: BMI at or above 30, or BMI at or above 27 with at least one weight-related comorbidity, plus a record of prior lifestyle intervention [3]. This is general planning guidance, not a guarantee of coverage outcome for any specific plan.

Safety Monitoring That Continues (or Should Continue) After Transition

Thyroid C-Cell Warning

Liraglutide has a boxed warning concerning thyroid safety based on animal studies. According to the FDA label, liraglutide "causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice." [3] Human risk from these findings remains unclear, though the label advises against use in individuals with personal or family history of medullary thyroid carcinoma or MEN2. Routine calcitonin or thyroid ultrasound screening is not recommended for patients receiving liraglutide due to lack of established evidence-based protocols; instead, counseling should emphasize reporting neck masses, swallowing difficulties, voice changes, or persistent hoarseness [3]. When transitioning patients to adult care, ensure the medical record documents any such symptoms that occurred during liraglutide therapy, and confirm that the receiving adult provider has reviewed the relevant warning signs requiring ongoing vigilance.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists, and patients should be told to stop the medication and seek evaluation for severe, persistent abdominal pain [3]. A 2018 meta-analysis of cardiovascular outcome trials for GLP-1 agonists did not find a statistically significant increase in pancreatitis as a secondary safety endpoint [10], but this was not the primary purpose of those trials, and isolated case reports continue to appear in the literature. The absolute risk in this population has not been separately quantified.

Cardiovascular Monitoring

The LEADER trial, in 9,340 adults with type 2 diabetes at elevated cardiovascular risk, found that liraglutide 1.8 mg/day reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 13% versus placebo (hazard ratio 0.87, 95% CI 0.78-0.97, P<0.001) [11]. This is adult data from a higher-risk population; no pediatric or young-adult cardiovascular outcomes trial exists, so this benefit should not be assumed to transfer directly to a transitioning adolescent. Adult providers should still use the first post-transfer visit to establish a fresh baseline for blood pressure, lipids, and HbA1c.

When a Child Under 10 Reaches an On-Label Age

Occasionally a child treated off-label at an academic center reaches age 10 or 12 and becomes eligible for an on-label indication for the first time, despite years of prior exposure.

Re-Establishing Consent

When a patient crosses from off-label to on-label use, the receiving provider should formally re-obtain informed consent using the current approved labeling as the basis for that conversation, documenting that the patient (and guardian, if still a minor) understands the now-applicable indication, the thyroid C-cell warning, and the ongoing monitoring plan. Prior off-label use does not need to be recharacterized, but the new consent should stand on its own.

Behavioral Continuity

The 2023 AAP clinical practice guideline for pediatric obesity treats medication as an adjunct to intensive behavioral intervention, not a replacement for it [12]. Adult providers receiving these patients should connect them with dietitians and behavioral health support rather than assuming medication alone will sustain results.

A 2022 analysis in Diabetes, Obesity and Metabolism examining semaglutide withdrawal in adults found that roughly two-thirds of lost weight was regained within a year of stopping therapy [13]. This is adult, semaglutide-specific data, used here only as the best available proxy for what a transitioning adolescent or young adult might expect if liraglutide is interrupted, not a liraglutide-specific finding.

A Practical Checklist for the Pediatric Clinician Preparing a Handoff

• Start early. Begin transition conversations around age 16, not the final pediatric visit.
• Call the adult provider directly. A warm handoff reduces the chance a patient falls out of care in the first months after transfer.
• Document total liraglutide exposure. Duration, peak dose reached, and any dose reductions and why.
• Flag the insurance gap. Confirm with the family whether coverage is expected to lapse between the last pediatric prescription and the first adult one, and start that conversation early.
• Provide the FDA medication guide. The Saxenda medication guide is publicly available and written for a general reading level [3].
• Ask about injection fatigue. A patient who has injected daily since age 12 may become quietly avoidant by 17; a direct conversation can surface silent discontinuation before it becomes a treatment gap.